SELLAS Life Sciences Group, Inc. (SLS)
13.76
-1.10
(-7.40%)
USD |
NASDAQ |
Nov 20, 11:00
SELLAS Life Sciences Group Free Cash Flow : -27.30M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -27.30M |
| June 30, 2026 | -28.42M |
| March 31, 2026 | -28.16M |
| December 31, 2025 | -28.39M |
| September 30, 2025 | -30.62M |
| June 30, 2025 | -31.36M |
| March 31, 2025 | -33.71M |
| December 31, 2024 | -35.40M |
| September 30, 2024 | -38.57M |
| June 30, 2024 | -37.66M |
| March 31, 2024 | -35.54M |
| December 31, 2023 | -36.91M |
| September 30, 2023 | -36.24M |
| June 30, 2023 | -35.09M |
| March 31, 2023 | -33.29M |
| December 31, 2022 | -28.31M |
| September 30, 2022 | -23.63M |
| June 30, 2022 | -23.76M |
| March 31, 2022 | -22.90M |
| December 31, 2021 | -26.02M |
| September 30, 2021 | -17.62M |
| June 30, 2021 | -15.37M |
| March 31, 2021 | -13.86M |
| December 31, 2020 | -10.42M |
| September 30, 2020 | -18.02M |
| Date | Value |
|---|---|
| June 30, 2020 | -18.21M |
| March 31, 2020 | -19.48M |
| December 31, 2019 | -17.64M |
| September 30, 2019 | -18.02M |
| June 30, 2019 | -28.37M |
| March 31, 2019 | -30.01M |
| December 31, 2018 | -30.42M |
| September 30, 2018 | -27.61M |
| June 30, 2018 | -15.84M |
| March 31, 2018 | -5.988M |
| December 31, 2017 | -10.99M |
| September 30, 2017 | -17.25M |
| June 30, 2017 | -27.06M |
| March 31, 2017 | -42.10M |
| December 31, 2016 | -44.92M |
| September 30, 2016 | -52.28M |
| June 30, 2016 | -49.04M |
| March 31, 2016 | -49.46M |
| December 31, 2015 | -48.31M |
| September 30, 2015 | -43.81M |
| June 30, 2015 | -49.02M |
| March 31, 2015 | -50.39M |
| December 31, 2014 | -48.40M |
| September 30, 2014 | -51.24M |
| June 30, 2014 | -45.13M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.87B |
| TG Therapeutics, Inc. | 85.56M |
| Capricor Therapeutics, Inc. | -146.29M |
| Relay Therapeutics, Inc. | -214.02M |
| ImmunityBio, Inc. | -297.09M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -5.94M |
| Cash from Financing (Quarterly) | 2.308M |
| Free Cash Flow Per Share (Quarterly) | -0.0293 |
| Free Cash Flow to Equity (Quarterly) | -5.802M |
| Free Cash Flow to Firm (Quarterly) | -5.94M |
| Free Cash Flow Yield | -0.97% |